Treatment with Orenitram (oral treprostinil) is associated with lower healthcare-related costs than treatment with Uptravi (selexipag) in people with pulmonary arterial hypertension (PAH), a new study suggests. The study, “Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective…
News
Among people with chronic thromboembolic pulmonary hypertension (CTEPH), certain anticoagulants may reduce the risk of serious bleeding more than others, a new study shows. The study, “Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational…
The Phase 2 HELP study testing levosimendan as a potential treatment for pulmonary hypertension (PH) has exceeded its target number and is fully enrolled, Tenax Therapeutics announced. The trial (NCT03541603), testing the potential therapy in PH patients with heart failure…
Bellerophon Therapeutics has reached an agreement with the U.S. Food and Drug Administration (FDA) setting the design of an upcoming, pivotal Phase 3 clinical trial testing INOpulse, an investigational therapy, in people with pulmonary fibrosis (PF) who are at risk of pulmonary hypertension (PH). PH-PF is characterized…
The number of both new and existing cases of pulmonary arterial hypertension (PAH) in the southwestern U.S. population was found in a recent study to be higher than that reported in the largest U.S. PH registry, called REVEAL, or the Registry to Evaluate Early and Long-term PAH.
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still lacking treatment. And federal incentives to boost treatment development for these rare diseases have primarily focused not on creating new…
Genetic screening of patients with persistent pulmonary hypertension of the newborn (PPHN) found three rare mutations associated with the condition, suggesting it has a genetic basis, a study reports. The researchers also found that a link between PPHN and genetic variants…
Men with pulmonary arterial hypertension (PAH) are more likely to carry mutations in the BMPR2 gene, a known genetic risk factor for PAH, a study from China found. Male PAH patients had more severe disease and were diagnosed at younger age than women. The results support the therapeutic potential…
In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare campaign was aimed at uplifting people with rare diseases by encouraging them to share their stories and perspectives. The…
The U.S. Food and Drug Administration (FDA) granted an extra clearance to the Unity Subcutaneous Delivery System for Remodulin (treprostinil) Injection, also known as the Remunity pump, allowing the system to be used with drug cassettes that have been prefilled by specialty pharmacies. The Remunity system allows for constant, subcutaneous…
Beginning on Feb. 29, Rare Disease Day, chapters from notable scientific books and clinical review articles covering rare disorders will be available free-of-charge from Elsevier. The offer runs through April 30, and aims to supports work by researchers and clinicians into a better understanding of and treatments for rare diseases, as well…
You literally can’t miss it in the news these days — millions (if not billions) of people all over the world are talking about the increasing spread of “the new (novel) Coronavirus.” According to the Center for Disease Control (CDC), the earliest cases of COVID-19 began in the city of…
